BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhai G, Li M, Wang Y, Wu J. Drug-Induced Liver Disturbance During the Treatment of COVID-19. Front Pharmacol 2021;12:719308. [PMID: 34483929 DOI: 10.3389/fphar.2021.719308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Ali FEM, Abd El-Aziz MK, Ali MM, Ghogar OM, Bakr AG. COVID-19 and hepatic injury: cellular and molecular mechanisms in diverse liver cells. World J Gastroenterol 2023; 29(3): 425-449 [PMID: 36688024 DOI: 10.3748/wjg.v29.i3.425] [Reference Citation Analysis]
2 Temirbulatov II, Kryukov AV, Mirzaev KB, Denisenko NP, Abdullaev SP, Kachanova AA, Sozaeva ZA, Zhiryakova AS, Shevchuk YV, Vechorko VI, Averkov OV, Sychev DA. Evaluation of the association of CES1 (rs2244613) polymorphisms with the safety of remdesivir in hospitalized patients with COVID-19. Medicinskij sovet 2023. [DOI: 10.21518/2079-701x-2022-16-23-304-309] [Reference Citation Analysis]
3 Zhao SW, Li YM, Li YL, Su C. Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments. World J Gastroenterol 2023; 29(2): 241-256 [PMID: 36687127 DOI: 10.3748/wjg.v29.i2.241] [Reference Citation Analysis]
4 Lin K, Gausman V, Poles M, Popov V. Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19. ACG Case Rep J 2022;9:e00866. [PMID: 36212242 DOI: 10.14309/crj.0000000000000866] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Wong CKH, Au ICH, Cheng WY, Man KKC, Lau KTK, Mak LY, Lui SL, Chung MSH, Xiong X, Lau EHY, Cowling BJ. Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study. Aliment Pharmacol Ther 2022;56:121-30. [PMID: 35318694 DOI: 10.1111/apt.16894] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
6 Wu J, Wang Y, Cai Z, Lin Z, Huang H, Wang D, Yu J, Jiang B, Zhao X, Zhai G, Lin S, Li L, Cao H, Rasheed F. Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China. Advanced Gut & Microbiome Research 2022;2022:1-10. [DOI: 10.1155/2022/7009876] [Reference Citation Analysis]
7 Marc F, Moldovan C, Hoza A, Restea P, Sachelarie L, Romila LE, Suteu C, Farcas DM. Evaluation of Hepatic Biochemical Parameters during Antiviral Treatment in COVID-19 Patients. Biology (Basel) 2021;11:13. [PMID: 35053011 DOI: 10.3390/biology11010013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]